SOM230: A new therapeutic modality for Cushing's disease

被引：0
|
作者：
Lewis, Ian [1 ]
Pless, Janos [2 ]
Kneuer, Rainer [1 ]
Silva, Antonio [2 ]
Hoyer, Daniel [2 ]
Weckbecker, Gisbert [2 ]
Bruns, Christian [2 ]
Schmid, Herbert A. [2 ]
机构：
[1] Novartis Inst Biomed Res, Dept Exploratory Med Chem Global Discovery Chem, CH-4002 Basel, Switzerland
[2] Novartis Inst Biomed Res, Dept Autoimmune Oncol & Nervous Syst Res, CH-4002 Basel, Switzerland
来源：
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY | 2013年 / 246卷
关键词：
D O I：
暂无
中图分类号：
O6 [化学];
学科分类号：
0703 ;
摘要：
164-MEDI
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Phase II trial of SOM230 (pasireotide LAR) in patients with unresectable hepatocellular carcinoma
    Feun, Lynn G.
    Wangpaichitr, Medhi
    Li, Ying-Ying
    Kwon, Deukwoo
    Richman, Stephen P.
    Hosein, Peter J.
    Savaraj, Niramol
    JOURNAL OF HEPATOCELLULAR CARCINOMA, 2018, 5 : 9 - 15
  • [42] Pasireotide: A New Therapeutic Option in the Treatment of Cushing's Disease
    Luger, A.
    Gasser, R. W.
    Hofmann, A.
    Hofle, G.
    Pichler, R.
    Piswanger-Solkner, J.
    Schnack, C.
    AUSTRIAN JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM, 2012, 5 : 2 - 5
  • [43] SOM230, a new somatostatin analogue, is highly effective in the therapy of growth hormone/prolactin-secreting pituitary adenomas
    Fedele, Monica
    De Martino, Ivana
    Pivonello, Rosario
    Ciarmiello, Andrea
    De Caro, M. Laura Del Basso
    Visone, Rosa
    Palmieri, Dario
    Pierantoni, Giovanna M.
    Arra, Claudio
    Schmid, Herbert A.
    Hofland, Leo
    Lombardi, Gaetano
    Colao, Annamaria
    Fusco, Alfredo
    CLINICAL CANCER RESEARCH, 2007, 13 (09) : 2738 - 2744
  • [44] A single-dose comparison of the acute effects between the new somatostatin analog SOM230 and octreotide in acromegalic patients
    van der Hoek, J
    de Herder, WW
    Feelders, RA
    van der Lely, AJ
    Uitterlinden, P
    Boerlin, V
    Bruns, C
    Poon, KW
    Lewis, I
    Weckbecker, G
    Krahnke, T
    Hofland, LJ
    Lamberts, SW
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2004, 89 (02): : 638 - 645
  • [45] Effects of SOM230 on in vitro secretion of glucagon and insulin from isolated mouse pancreatic islets
    Singh, V
    Zacharias, S
    Mergler, S
    Grötzinger, C
    Wiedenmann, B
    Strowski, MZ
    EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2005, 152
  • [46] Tolerability of SOM230, a novel multiligand somatostatin analogue, when given by continuous subcutaneous infusion
    Petersenn, S
    Unger, N
    Glusman, J
    Hosius, C
    Tran, LL
    Mann, K
    EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2005, 152
  • [47] Preclinical evidences suggest new treatment options for endocrine disorders: Pasireotide (SOM230) and Everolimus (RAD001)
    Schmid, H. A.
    ANNALES D ENDOCRINOLOGIE, 2008, 69 (02) : 162 - 163
  • [48] The novel somatostatin ligand (SOM230) regulates human and rat anterior pituitary hormone secretion
    Murray, RD
    Kim, K
    Ren, SG
    Lewis, I
    Weckbecker, G
    Bruns, C
    Melmed, S
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2004, 89 (06): : 3027 - 3032
  • [49] Baseline Characteristics and Urine Free Cortisol (UFC) Variability of 162 Patients Enrolled in a Randomized, Double-Blind Phase III Study Assessing the Efficacy and Safety of Pasireotide (SOM230) in Patients with Cushing's Disease.
    Petersenn, S.
    Newell-Price, J.
    Findling, J. W.
    Gu, F.
    Maldonado, M.
    Sen, K.
    Salgado, L. R.
    Colao, A.
    Biller, B. M. K.
    ENDOCRINE REVIEWS, 2010, 31 (03)
  • [50] SOM230 combined with celecoxib prolongs the survival in nude mice with HepG-2 xenografts
    Xie, Yan
    Chen, Shuang
    Wang, Chun-hui
    Tang, Cheng-wei
    CANCER BIOLOGY & THERAPY, 2011, 12 (01) : 86 - 92
12345